Ironwood Pharmaceuticals | IRWD - Equity Capital And Reserves


Ironwood Pharmaceuticals reported $-264.16M in Equity Capital and Reserves for its fiscal quarter ending in September of 2025.





Equity Capital And Reserves Change Date
Acadia Pharmaceuticals USD 917.27M 94.89M Sep/2025
Agios Pharmaceuticals USD 1.19B 91.22M Dec/2025
Akebia Therapeutics USD 32.61M 8.98M Dec/2025
Almirall EUR 1.49B 24.03M Dec/2025
Alnylam Pharmaceuticals USD 789.18M 555.28M Dec/2025
Amarin USD 459.28M 387K Dec/2025
Ardelyx USD 166.95M 12.67M Dec/2025
Astellas Pharma JPY 1.83T 65.92B Mar/2026
AstraZeneca USD 48.67B 2.78B Dec/2025
Charles River Laboratories USD 3.16B 240.82M Dec/2025
Coherus Biosciences USD 61.01M 26.76M Dec/2025
Emergent BioSolutions USD 649.3M 47.9M Dec/2023
Esperion Therapeutics USD -301.96M 149.4M Dec/2025
Halozyme Therapeutics USD 48.81M 455.1M Dec/2025
Incyte USD 5.62B 455.37M Mar/2026
Ironwood Pharmaceuticals USD -264.16M 44M Sep/2025
Karyopharm Therapeutics USD -292.93M 23.67M Dec/2025
Lexicon Pharmaceuticals USD 107.54M 12.62M Dec/2025
MacroGenics USD 55.59M 11.41M Dec/2025
Moderna USD 8.65B 680M Dec/2025
Myriad Genetics USD 368M 4.8M Dec/2025
Pacira USD 693.11M 34.1M Dec/2025
PTC Therapeutics USD -205.31M 49.56M Dec/2025
Puma Biotechnology USD 115.27M 10.55M Sep/2025
Sarepta Therapeutics USD 1.14B 179.5M Dec/2025
Takeda JPY 7.64T 513.39B Dec/2025
Ultragenyx Pharmaceutical USD 9.16M 142.13M Sep/2025
Vanda Pharmaceuticals USD 327.19M 138.81M Dec/2025